Comparative Pharmacology
Head-to-head clinical analysis: ANDEMBRY versus HUMEGON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDEMBRY versus HUMEGON.
ANDEMBRY vs HUMEGON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.
HUMEGON (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from the urine of postmenopausal women. It acts by stimulating ovarian follicular growth and maturation in women and spermatogenesis in men via binding to FSH and LH receptors on target cells.
ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.
75 to 150 IU subcutaneously or intramuscularly once daily for 7 to 12 days, adjusted based on follicular response.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged up to 20-25 hours in patients with moderate to severe hepatic impairment.
Terminal half-life approximately 23-24 hours (range 20-30 h) for FSH and LH activity; clinical significance: once-daily dosing achieves steady-state in 4-5 half-lives (approx. 5 days).
Primarily renal excretion of unchanged drug (approximately 70-80%) and as metabolites (10-15%); biliary/fecal elimination accounts for less than 10%.
Primarily renal (90-95% as intact hormone and metabolites); biliary/fecal excretion minor (<5%).
Category C
Category C
Gonadotropin
Gonadotropin